Recursion director grants RSUs, sells 3,963 shares

RECURSION PHARMACEUTICALS, INC. director Namandje Bumpus reported both an equity award and a small share sale.

(Neutral)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

RECURSION PHARMACEUTICALS, INC. director Namandje Bumpus reported both an equity award and a small share sale. On June 17, 2026, Bumpus received a grant of 88,424 restricted stock units under the company’s Outside Director Compensation Policy. These units vest on the earlier of June 17, 2027 or the day before the 2027 annual stockholders’ meeting, subject to continued service.

On June 18, 2026, Bumpus sold 3,963 shares of Class A Common Stock in an open‑market transaction at $3.18 per share, executed under a Rule 10b5‑1 trading plan adopted on March 3, 2026. After the reported transactions, Bumpus directly owned 127,632 shares of Class A Common Stock.

Insider Trade Summary 10b5-1

Net Seller: 3,963 shares

Net Sell 2 txns

Insider Bumpus Namandje

Role Director

Sold 3,963 shs ($13K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	3,963	$3.18	$13K
Grant/Award	Class A Common Stock	88,424	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 127,632 shares (Direct)

Footnotes (2)

F1. Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.
F2. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.

Key Figures

RSU grant size: 88,424 shares RSU vesting date: June 17, 2027 Shares sold: 3,963 shares +5 more

8 metrics

RSU grant size 88,424 shares Restricted stock units granted June 17, 2026

RSU vesting date June 17, 2027 Or day before 2027 annual meeting, service-based

Shares sold 3,963 shares Class A Common Stock sold June 18, 2026

Sale price $3.18 per share Open-market sale of Class A Common Stock

Post-transaction holdings 127,632 shares Class A Common Stock directly owned after transactions

RSU grant price $0.00 per unit Grant/award acquisition with no purchase price

Net share activity -3,963 shares Net buy/sell direction reported as net-sell

10b5-1 plan adoption date March 3, 2026 Covers the June 18, 2026 open-market sale

Key Terms

restricted stock units, Outside Director Compensation Policy, Rule 10b5-1 trading plan, open-market sale, +1 more

5 terms

restricted stock units financial

"Represents a grant of restricted stock units automatically granted pursuant"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Outside Director Compensation Policy financial

"automatically granted pursuant to the Issuer's Outside Director Compensation Policy"

Rule 10b5-1 trading plan regulatory

"This transaction is pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Class A Common Stock financial

"security_title": "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Namandje Bumpus report at Recursion (RXRX)?

Namandje Bumpus reported receiving 88,424 restricted stock units and selling 3,963 Class A shares. The award was a director grant, and the sale was an open‑market transaction executed under a pre‑arranged Rule 10b5‑1 trading plan.

How many Recursion (RXRX) shares did Namandje Bumpus sell and at what price?

Bumpus sold 3,963 shares of Recursion Class A Common Stock at $3.18 per share. The June 18, 2026 transaction was an open‑market sale made under a Rule 10b5‑1 trading plan adopted on March 3, 2026.

What equity award did Namandje Bumpus receive from Recursion (RXRX)?

Bumpus received a grant of 88,424 restricted stock units as an automatic award under Recursion’s Outside Director Compensation Policy. The units vest based on service, rather than purchase, and carry no cash exercise price per share.

When do Namandje Bumpus’s Recursion (RXRX) restricted stock units vest?

The 88,424 restricted stock units will vest on the earlier of June 17, 2027 or the day before Recursion’s 2027 annual meeting of stockholders. Vesting is contingent on Bumpus’s continued service to the company through that date.

How many Recursion (RXRX) shares does Namandje Bumpus hold after these transactions?

Following the reported grant and sale, Bumpus directly owned 127,632 shares of Recursion Class A Common Stock. This post‑transaction holding reflects the net position after receiving restricted stock units and selling 3,963 shares in the market.

Was Namandje Bumpus’s sale of Recursion (RXRX) shares pre-planned?

Yes. A footnote states the June 18, 2026 sale of 3,963 shares was executed under a Rule 10b5‑1 trading plan. That plan was adopted on March 3, 2026, indicating the disposition followed a pre‑arranged trading schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/22/2026 - 04:32 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bumpus Namandje

(Last)

(First)

(Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY

UTAH

84101

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	06/17/2026		A⁽¹⁾		88,424	A	$0	131,595	D
Class A Common Stock	06/18/2026		S⁽²⁾		3,963	D	$3.18	127,632	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

2. This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR